Once-A-Year Non-Injectable Byetta
The DUROS delivery system aims to reshape the way diabetes is treated by offering patients and their health care providers with a more convenient long term treatment regiment. The result is the investigational treatment now in late stage development — ITCA 650. As part of a robust clinical trial program to develop ITCA 650, Intarcia paired the DUROS device with exenatide. ITCA 650 is a matchstick-sized, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent treatment of exenatide therapy for up to a year. Exenatide, the active agent in ITCA 650, has been approved in the U.S., Europe and many other markets. Presented at the European Association for the Study of Diabetes (EASD) 47th Annual Meeting. See how it works (pdf).
For more information and to access a short video, please follow this link to Intarcia Therapeutics. (The video link is about halfway down on the right-hand side.)